Please assess the completion status of the following clinical trial:

Trial Title: CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Has end-stage renal disease (ESRD) and has been on hemodialysis 3 times per week for at least 3 months prior to the start of screening;~* Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction ratio measurements ≥65%, or 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis days during the 3 months period prior to screening;~* Prior to Treatment:~  * Has completed at least 3 Worst Itching Intensity NRS questionnaires from the start of the Run-in Period up to and including the pre-dose assessment on Day 1;~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Known noncompliance with dialysis treatment that in the opinion of the investigator would impede completion or validity of the study;~* Scheduled to receive a kidney transplant during the study;~* New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening;~* New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening;~* Received another investigational drug within 30 days or five half-lives (whichever is longer) prior to the start of dosing or is planning to participate in another interventional clinical study while enrolled in this study;~* Has pruritus only during the dialysis session (by patient report);~* Is receiving ongoing ultraviolet B treatment and/or anticipates receiving such treatment during the study;~* Participated in a previous clinical study with CR845.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CR845 0.5mcg/kg (Type: EXPERIMENTAL): IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

Based on this trial design, predict the completion outcome and termination type (if applicable).